We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/LAG-3 as a dual-modulator of neuroimmune surveillance and α-synuclein propagation in Parkinson’s disease and Lewy body dementia
PeriodicalsMedical Sciences

LAG-3 as a dual-modulator of neuroimmune surveillance and α-synuclein propagation in Parkinson’s disease and Lewy body dementia

Checking your access to this record.

Abstract & Overview

The emergence of immune checkpoint pathways as central regulators of neurodegeneration has reshaped our understanding of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Among these, lymphocyte-activation gene 3 (LAG-3) has gained prominence not only as a classical immune checkpoint molecule but also as a neuronal receptor for pathogenic α-synuclein fibrils. This review proposes the novel hypothesis that LAG-3 functions as a dual-modulator in α-synucleinopathies facilitating the pathological spread of misfolded α-synuclein across neuronal networks while concurrently impairing neuroimmune clearance mechanisms via T cell exhaustion and microglial suppression. Recent studies have demonstrated that LAG-3 selectively binds α-synuclein fibrils, promoting their internalization and prion-like propagation in both experimental models and human post-mortem tissues. Simultaneously, LAG-3 expression on CNS-infiltrating and resident immune cells contributes to a suppressive immunological microenvironment, impairing phagocytosis and promoting disease progression. This dual role situates LAG-3 at a mechanistic crossroads between aggregate transmission and immune dysfunction. This review synthesizes emerging data on LAG-3’s structure, neuronal expression, immune interactions, and translational relevance, highlighting its potential as a therapeutic target and biomarker. Innovations in Nano body engineering, CNS-penetrant inhibitors, and multi-omic biomarker strategies are also discussed. By positioning LAG-3 as both a vector of propagation and a checkpoint of immune resilience, this paper offers a novel framework for rethinking targeted immunomodulation in neurodegenerative diseases.

Cite this record

A. M. Mukherjee (2026). LAG-3 as a dual-modulator of neuroimmune surveillance and α-synuclein propagation in Parkinson’s disease and Lewy body dementia. Discover Neuroscience, 21(1). https://doi.org/10.1186/s13064-026-00259-4

Copy in another style

Mukherjee, A. M. (2026). LAG-3 as a dual-modulator of neuroimmune surveillance and α-synuclein propagation in Parkinson’s disease and Lewy body dementia. Discover Neuroscience, 21(1). https://doi.org/10.1186/s13064-026-00259-4
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.